According to results from the double-blind, randomized, placebo-controlled inMIND trial, the addition of tafasitimab to lenalidomide and rituximab therapy demonstrated safety and efficacy for patients with relapsed/refractory (R/R) follicular lymphoma (FL).

These results were presented by Christina Poh, MD, Fred Hutchinson Cancer Center, Seattle, Washington, at the 66^th ASH Annual Meeting in San Diego, California.

Among patients who have had more than 1 prior line of therapy, lenalidomide and rituximab is a standard treatment with limited durability. Previous research has found that the addition of tafasitimab to standard lenalidomide therapy is efficacious for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). To expand on these findings, researchers conducted a phase 3, multicenter trial to determine the efficacy and safety of additional tafasitimab to lenalidomide and rituximab treatment in patients with R/R FL

“This study is the first to validate combining 2 mAbs (anti-CD 19 with anti-CD20) in the treatment of lymphoma,” the researchers concluded, “Tafa [tafasitimab] +len [lenalidomide] + R [rituximab] can be administered in community as well as academic settings and represents a potential new standard of care option for patients with R/R FL.”

Transcript:

Hi, I am Christina Poh. I am a medical oncologist and a clinical researcher specializing in lymphomas at the Fred Hutchinson Cancer Center in Seattle, Washington. Today I'm going to be talking about the inMIND study, which is a study looking at the addition of tafasitimab to rituximab with lenalidomide in follicular lymphoma and marginal zone lymphoma.

Just a little bit of a background: follicular lymphoma and marginal zone lymphomas are both indolent lymphomas, and although we do have multiple treatments for these 2 disease indications, currently all the treatments are still palliative in terms of the disease is not curable. Better, more effective, more treatment options are needed in this case.

inMIND is a randomized phase 3 double-blinded placebo controlled multicenter study looking at the addition of tafasitimab to rituximab with lenalidomide in relapsed/ refractory, low-grade follicular and marginal zone lymphoma.

The primary end point for this study was PFS for the follicular lymphoma patient population. This was a 548-patient population study and in this study we did indeed see a prolongation of PFS with the tafasitimab-containing arm. The study did meet its primary end points. Specifically, the median PFS was 22.4 months versus 13.9 months for with and without tafasitimab respectively. This benefit was consistent and seen across all pre-specified subgroups. For example, the POD24 follicular lymphoma population, the heavily pretreated patient population, as well as the patients who were refractory to prior anti-CD20 monoclonal antibody.

The overall survival data is currently immature, but the trend is that it is in favor of the tafasitimab-containing arm as well. In terms of side effects, the adverse event profile is manageable across and is expected for what we're seeing with these agents.

This is a very exciting study. This study is the first to validate the approach of combining 2 monoclonal antibodies simultaneously for the treatment of relapsed/refractory follicular lymphoma, so specifically anti-CD19 and anti-CD20. Super exciting and potentially practice changing for this patient population as well.

Source:

Sehn LH, Luminari S, Scholz CW, et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND). Dec 7-10, 2024; San Diego, CA. Abstract: LBA-1